Decreased defluorination using the novel betacell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-13

  Jahan, Mahabuba ^a   Eriksson, Olof ^b   Johnström, Peter ^a,c   Korsgren, Olle ^b   Sundin, Anders ^a,b   Johansson, Lars ^b,d   Halldin, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Beta cell mass; Dihydrotetrabenazine; PET; VMAT2

Indexed keywords

FLUORINE 18; FLUOROETHYL DIHYDRITETRABENZINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ALKYLATION; ARTICLE; BINDING AFFINITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEFLUORINATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; NONHUMAN; PIGLET; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 84861652554     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-33     Document Type: Article

References (25)

1. Koeppe RA, Gilman S, Joshi A, Liu SY, Little R, Junck L, Heumann M, Frey KA, Albin RL: 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005, 46:936-944.
2. Martin WR, Wieler M, Stoessl AJ, Schulzer M: Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008, 63:388-394.
3. Anlauf M, Eissele R, Schafer MKH, Eiden LE, Arnold R, Pauser U, Klöppel G, Weihe E: Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003, 51:1027-1040.
4. Fagerholm V, Mikkola KK, Ishizu T, Arponen E, Kauhanen S, Nagren K, Solin O, Nuutila P, Haaparanta M: Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 2010, 51:1439-1446.
5. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, Kilbourn M, Jurewicz A, Herold K, Liu E, Hardy MA, Van Heertum R, Harris PE: Visualizing pancreatic-cell mass with [11C]DTBZ. Nucl Med Biol 2006, 33:855-864.
6. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, Prince M, Maffei A, Mann JJ, Butler PC, Van Heertum R, Leibel RL, Ichise M, Harris PE: 11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009, 50:382-389.
7. Eriksson O, Jahan M, Johnström P, Korsgren O, Sundin A, Halldin C, Johansson L: In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol 2010, 37:357-363.
8. Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, Skovronsky D, Chang HP, Kung MP, Yen TC: Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med 2010, 51:1480-1485.
9. Tsao HH, Lin KJ, Juang JH, Skovronsky DM, Yen TC, Wey SP, Kung MP: Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol 2010, 37:413-419.
10. Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, Skovronsky D, Kilbourn MR, Kung HF: In vivo imaging of beta-cell mass in rats using F-18-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 2008, 49:1171-1176.
11. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF: Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006, 33:685-694.
12. Kung HF, Lieberman BP, Zhuang ZP, Oya S, Kung MP, Choi SR, Poessl K, Blankemeyer E, Hou C, Skovronsky D, Kilbourn M: In vivo imaging of vesicular monoamine transporter 2 in pancreas using an 18F epoxide derivative of tetrabenazine. Nucl Med Biol 2008, 35:825-837.
13. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST: Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008, 49:68-78.
14. Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, Mozley PD, Dobson D, Shchukin E, Innis RB, Farde L: PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004, 53:57-67.
15. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK, Felder CC, Halldin C, Schaus JM: Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem 2008, 51:5833-5842.
16. Takano A, Gulyas B, Varrone A, Karlsson P, Schou M, Airaksinen AJ, Vandenhende F, Tauscher J, Halldin C: Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S, S)-[18F]FMeNER-D2. Eur J Nucl Med Mol Imaging 2008, 35:153-157.
17. Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Donohue SR, Pike VW, Halldin C, Innis RB: Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands. J Nucl Med 2010, 51:112-120.
18. Gunn RN, Gunn SR, Cunningham VJ: Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001, 21:635-652.
19. Zhang MR, Tsuchiyama A, Haradahira T, Yoshida Y, Furutsuka K, Suzuki K: Development of an automated system for synthesizing 18F-labeled compounds using [18F]fluoroethyl bromide as a synthetic precursor. Appl Radiat Isot 2002, 57:335-342.
20. Piert M, Zittel TT, Becker GA, Jahn M, Stahlschmidt A, Maier G, Machulla HJ, Bares R: Assessment of porcine bone metabolism by dynamic. J Nucl Med 2001, 42:1091-100.
21. Melander L, Saunder WH Jr: Reaction Rates of Isotopic Molecules. New York: John Wiley & Sons; 1980.
22. Zhang MR, Maeda J, Ito T, Okauchi T, Ogawa M, Noguchi J, Suhara T, Halldin C, Suzuki K: Synthesis and evaluation of N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoromethoxy-d(2)-5-methoxybenzy l) acetamide: a deuterium-substituted radioligand for peripheral benzodiazepine receptor. Bioorg Med Chem 2005, 13:1811-1818.
23. Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, Schlyer DJ, Pappas N, Alexoff DL, Patlak C, Wolf A: Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995, 36:1255-1262.
24. Staley JK, Van Dyck CH, Tan PZ, Al Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin RM, Innis RB: Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. Nucl Med Biol 2001, 28:271-279.
25. Anlauf M, Schafer MK, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, Horny HP, Parwaresch R, Hartschuh W, Eiden LE, Klöppel G, Weihe E: Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. J Histochem Cytochem 2006, 54:201-213.